Overview

Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Status:
Not yet recruiting

Trial end date:
2025-04-30

Target enrollment:

Participant gender:

Summary

This is a Phase 1/2, multicenter, open-label, dose-escalation study that will determine the MTD and RP2D of L-Annamycin in combination with cytarabine for the treatment of subjects with AML that is refractory to or relapsed after induction therapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Moleculin Biotech, Inc.

Treatments:

Annamycin
Cytarabine